Loading...
Cardiff Oncology, Inc.
CRDF•NASDAQ
Healthcare
Biotechnology
$2.51
$-0.13(-4.92%)
Cardiff Oncology, Inc. (CRDF) Financial Performance & Income Statement Overview
Explore the financials of Cardiff Oncology, Inc. (CRDF), including yearly and quarterly data on income, cash flow, and balance sheets.
Revenue Growth
39.96%
↑ 39.96%
Operating Income Growth
-7.13%
↓ 7.13%
Net Income Growth
-9.63%
↓ 9.63%
Operating Cash Flow Growth
-22.04%
↓ 22.04%
Operating Margin
-12784.00%
↓ 12784.00%
Gross Margin
77.41%
↑ 77.41%
Net Profit Margin
-12005.88%
↓ 12005.88%
ROE
-77.95%
↓ 77.95%
ROIC
-91.98%
↓ 91.98%
Cardiff Oncology, Inc. (CRDF) Income Statement & Financial Overview
View the income breakdown for Cardiff Oncology, Inc. CRDF across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $151000.00 | $165000.00 | $163000.00 | $205000.00 |
| Cost of Revenue | $96000.00 | $0.00 | $105000.00 | $102000.00 |
| Gross Profit | $55000.00 | $165000.00 | $58000.00 | $103000.00 |
| Gross Profit Ratio | $0.36 | $1.00 | $0.36 | $0.50 |
| R&D Expenses | $9.71M | $9.64M | $9.49M | $8.008M |
| SG&A Expenses | $3.01M | $3.13M | $3.11M | $3.03M |
| Operating Expenses | $12.72M | $12.77M | $12.60M | $11.04M |
| Total Costs & Expenses | $12.72M | $12.77M | $12.71M | $11.14M |
| Interest Income | $787000.00 | $741000.00 | $805000.00 | $926000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $96000.00 | $101000.00 | $105000.00 | $102000.00 |
| EBITDA | -$12.48M | -$12.50M | -$12.44M | -$10.83M |
| EBITDA Ratio | -$82.62 | -$75.76 | -$76.32 | -$52.83 |
| Operating Income | -$12.57M | -$12.60M | -$12.54M | -$10.93M |
| Operating Income Ratio | -$83.26 | -$76.37 | -$76.96 | -$53.33 |
| Other Income/Expenses (Net) | $785000.00 | $740000.00 | $767000.00 | $922000.00 |
| Income Before Tax | -$11.79M | -$11.86M | -$11.78M | -$10.01M |
| Income Before Tax Ratio | -$78.06 | -$71.88 | -$72.26 | -$48.83 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $58724.00 |
| Net Income | -$11.79M | -$11.86M | -$11.78M | -$10.01M |
| Net Income Ratio | -$78.06 | -$71.85 | -$72.26 | -$48.83 |
| EPS | -$0.25 | -$0.25 | -$0.26 | -$0.22 |
| Diluted EPS | -$0.25 | -$0.25 | -$0.26 | -$0.22 |
| Weighted Avg Shares Outstanding | $55.24M | $46.87M | $44.83M | $44.68M |
| Weighted Avg Shares Outstanding (Diluted) | $55.24M | $46.87M | $44.83M | $44.68M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan